lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

The First Report of the Prevalence of COVID-19 in Chronic Myelogenous Leukemia Patients in the Core Epidemic Area of China: A Multicentre, Cross-Sectional Survey

24 Pages Posted: 25 Mar 2020

See all articles by Dan-Yu Wang

Dan-Yu Wang

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology

Jing-Ming Guo

China Three Gorges University (CTGU) - Department of Hematology

Zhuang-Zhi Yang

Suizhou Central Hospital - Department of Hematology

Yong You

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology

Zhichao Chen

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology

Shi-Ming Chen

Hubei Polytechnic University - Department of Hematology

Hui Cheng

Wuhan No. 1 Hospital - Department of Hematology

You-Shan Zhang

The First People’s Hospital of Jingzhou - Department of Hematology

Dao-Zi Jiang

Wuhan University - Department of Hematology

Xue-Lan Zuo

Wuhan University - Department of Hematology

Xiao-Jian Zhu

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology

Jun Huang

First People's Hospital of Xiaogan City - Department of Hematology

Hong-Xiang Wang

Wuhan Central Hospital - Department of Hematology

Qing Li

Wuhan No. 1 Hospital - Department of Hematology

Qing Wu

Wuhan No. 5 Hospital - Department of Hematology

Zhi-Ping Huang

Jingzhou Central Hospital - Department of Hematology

Qi-Huan Liu

Hubei University of Medicine - Department of Hematology

Ying Bao

Hubei University of Medicine - Department of Hematology

Da-Lin Zhang

First People's Hospital of Tianmen - Department of Hematology

Xin-Hua Zhang

Government of the People's Republic of China - Department of Hematology

Zhe Zhao

Hubei Minzu University - Department of Hematology

Ren-Ying Ge

Xian Ning Center Hospital - Department of Hematology

Jie Du

Xiantao First People’s Hospital - Department of Hematology

Ya-Ping Wang

Wuhan Fifth Hospital - Department of Hematology

Hong-Bo Ren

The First People’s Hospital of Jingzhou - Department of Hematology

Hong Han

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology

Yun-Hui Wei

XiangZhou Hospital - Department of Hematology

Hang Xiang

Enshi Central Hospital - Department of Hematology

Chu-Cheng Wan

Hubei University of Medicine - Department of Hematology

You-Fang Zhao

China Three Gorges University (CTGU) - Department of Hematology

Bin Chen

Hubei Provincial Hospital of Traditional Chinese Medicine - Department of Hematology

Guo-Lin Yuan

Hubei University of Arts and Science - Department of Haematology

Li Meng

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology

Wei-Ming Li

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology

More...

Abstract

Background: Since late December 2019, the outbreak of the novel coronavirus disease, COVID-19, that began in Wuhan, has become endemic in China and more than 100 countries and regions in the world. There is no report about the prevalence of COVID-19 in CML patients untill now. We aimed to describe the clinical course, outcomes of CML patients with COVID-19 and prevalence of COVID-19 in CML patients.

Methods: In this multi-center survey, cross-sectional survey, observational study, the clinical data of CML patients with COVID-19 in each center were collected. Simultaneously, an online survey was conducted for information about the CML patients under the management at each center by asking the CML patients to complete a questionnaire,from February 15, 2020 to February 21, 2020. The questionnaire includes demographic data, place of residence, smoking status, CML diagnosis and treatment, comorbidities, combined medications, epidemiological history, symptoms (fever, cough, shortness of breath, etc) during the epidemic. Additional clinical data was collected on respondents suspected or confirmed to have COVID-19. We described and analyzed the prevalence of COVID-19 in CML patients, and focus on the clinical characteristics and outcomes of COVID-19 patients. Data were compared between the CML patients with optimal response and those with non-optimal response. The primary outcome was prevalence of COVID-19 in CML patients, as of Feb 21, 2020. Secondary outcomes included the history of epidemiology of CML patients, the clinical characteristics and outcomes of CML patients with COVID-19.

Findings: Of 392 respondents, 223(56.9%) were males, and 240(61.2%) were 50 years or younger. Only 10 patients took drugs irregularly due to the influence of the epidemic because of traffic control, pharmacies unable to operate normally, etc. In the history of epidemiology, there were 4 patients with definite contact with COVID-19, of which 3 were remote contact and 1 was close contact. 12 respondents had fever, cough or shortness of breath during the epidemic, 1 case (common type) was confirmed with COVID-19 and cured after treatment. 1 patient was clinically diagnosed and succumbed. 1 of 299 (0.3%) patients with an optimal response was diagnosed with COVID-19. Of the 50 patients who failed to respond to CML treatment or had a poor response, 1 patient (2%) had a clinical diagnosis of COVID-19.

Interpretation: While the 392 CML respondents required regular referrals to hospitals, they did not have much contact with COVID-19 patients during the outbreak. Patients who failed to achieved an optimal response to CML therapy appear more likely to have a symptomatic infection with SARS-CoV-2. Older patients with comorbidities are at increased risk of death.

Funding Statement: This work was supported by grants from the National Natural Science Foundation of China(NSFC)(81873440&81700142).

Declaration of Interests: All participants have no competing interests.

Ethics Approval Statement: The investigation was approved by the ethics committee of the Union hospital of the Tongji Medical College, which is part of the Huazhong University of Science and Technology.

Keywords: Chronic myelogenous leukemia; COVID-19

Suggested Citation

Wang, Dan-Yu and Guo, Jing-Ming and Yang, Zhuang-Zhi and You, Yong and Chen, Zhichao and Chen, Shi-Ming and Cheng, Hui and Zhang, You-Shan and Jiang, Dao-Zi and Zuo, Xue-Lan and Zhu, Xiao-Jian and Huang, Jun and Wang, Hong-Xiang and Li, Qing and Wu, Qing and Huang, Zhi-Ping and Liu, Qi-Huan and Bao, Ying and Zhang, Da-Lin and Zhang, Xin-Hua and Zhao, Zhe and Ge, Ren-Ying and Du, Jie and Wang, Ya-Ping and Ren, Hong-Bo and Han, Hong and Wei, Yun-Hui and Xiang, Hang and Wan, Chu-Cheng and Zhao, You-Fang and Chen, Bin and Yuan, Guo-Lin and Meng, Li and Li, Wei-Ming, The First Report of the Prevalence of COVID-19 in Chronic Myelogenous Leukemia Patients in the Core Epidemic Area of China: A Multicentre, Cross-Sectional Survey (3/13/2020). Available at SSRN: https://ssrn.com/abstract=3555226 or http://dx.doi.org/10.2139/ssrn.3555226

Dan-Yu Wang (Contact Author)

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology ( email )

Shenzhen
China

Jing-Ming Guo

China Three Gorges University (CTGU) - Department of Hematology ( email )

Zhuang-Zhi Yang

Suizhou Central Hospital - Department of Hematology ( email )

Suizhou
China

Yong You

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology ( email )

1277 Jiefang Avenue
Wuhan, 430022
China

Zhichao Chen

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology ( email )

1277 Jiefang Avenue
Wuhan, 430022
China

Shi-Ming Chen

Hubei Polytechnic University - Department of Hematology ( email )

Huangshi
China

Hui Cheng

Wuhan No. 1 Hospital - Department of Hematology ( email )

Wuhan
China

You-Shan Zhang

The First People’s Hospital of Jingzhou - Department of Hematology ( email )

JingZhou
China

Dao-Zi Jiang

Wuhan University - Department of Hematology ( email )

Wuhan
China

Xue-Lan Zuo

Wuhan University - Department of Hematology ( email )

China

Xiao-Jian Zhu

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology ( email )

China

Jun Huang

First People's Hospital of Xiaogan City - Department of Hematology ( email )

Xiaogan
China

Hong-Xiang Wang

Wuhan Central Hospital - Department of Hematology ( email )

Wuhan
China

Qing Li

Wuhan No. 1 Hospital - Department of Hematology ( email )

Wuhan
China

Qing Wu

Wuhan No. 5 Hospital - Department of Hematology ( email )

Wuhan
China

Zhi-Ping Huang

Jingzhou Central Hospital - Department of Hematology ( email )

Jingzhou
China

Qi-Huan Liu

Hubei University of Medicine - Department of Hematology ( email )

Shiyan
China

Ying Bao

Hubei University of Medicine - Department of Hematology ( email )

Xiangyang
China

Da-Lin Zhang

First People's Hospital of Tianmen - Department of Hematology ( email )

Tianmen
China

Xin-Hua Zhang

Government of the People's Republic of China - Department of Hematology ( email )

Wuhan
China

Zhe Zhao

Hubei Minzu University - Department of Hematology ( email )

Enshi
China

Ren-Ying Ge

Xian Ning Center Hospital - Department of Hematology ( email )

Xianning
China

Jie Du

Xiantao First People’s Hospital - Department of Hematology ( email )

Xiantao
China

Ya-Ping Wang

Wuhan Fifth Hospital - Department of Hematology ( email )

Wuhan
China

Hong-Bo Ren

The First People’s Hospital of Jingzhou - Department of Hematology ( email )

JingZhou
China

Hong Han

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology ( email )

Wuhan
China

Yun-Hui Wei

XiangZhou Hospital - Department of Hematology ( email )

Xiangyang
China

Hang Xiang

Enshi Central Hospital - Department of Hematology ( email )

Enshi
China

Chu-Cheng Wan

Hubei University of Medicine - Department of Hematology ( email )

Shiyan
China

You-Fang Zhao

China Three Gorges University (CTGU) - Department of Hematology ( email )

Yichang
China

Bin Chen

Hubei Provincial Hospital of Traditional Chinese Medicine - Department of Hematology ( email )

Wuhan
China

Guo-Lin Yuan

Hubei University of Arts and Science - Department of Haematology ( email )

Xiangyang, 441021
China

Li Meng

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology ( email )

China

Wei-Ming Li

Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Hematology ( email )

1277 Jiefang Avenue
Wuhan, 430022
China

Click here to go to TheLancet.com

Paper statistics

Abstract Views
824
Downloads
88